semaglutide nature Obesity drugs: huge study identifies new health risks Why your weight loss may

The Global GLP-1 Receptor Agonists Obesity Drugs Market was valued at USD 9.96 Billion in 2024 and is expected to reach USD 33.12 Billion by 2032, growing at a CAGR of 16.20% (2025-2032).

Youtheory, Multi, GLP-1 Support, 90 Capsules

2,250,000 People Have Already Made a Change

In this case report, we discuss the case of a 36-year-old female presenting to the Emergency Department with sudden-onset epigastric pain, subsequently diagnosed with acute pancreatitis

New research suggests GLP-1s may reduce the risks of blood clots and early death in people with both obesity and autoimmune disease

A recent Business Insider Business Insider feature highlights a major shift: 63% of trainers surveyed by NASM are already working with clients on GLP-1 medications